Skip to main content
SpringerLink
Log in

Sonidegib: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Sonidegib (Odomzo™) is an orally bioavailable, small molecule, Smoothened (SMO) receptor antagonist that is being developed by Novartis for the treatment of cancer. SMO is a G protein-coupled receptor-like molecule that is essential for the actions of the Hedgehog family of secreted proteins, which play a critical role in the development and homeostasis of many organs and tissues. Oral sonidegib is approved in Switzerland for the treatment of adult patients with advanced basal cell carcinoma (BCC) and in the US and EU for the treatment of adult patients with locally advanced BCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Submissions to other global authorities are being contemplated or planned. Additionally, phase I/II investigation is being conducted in other malignancies, including multiple myeloma, medulloblastoma, myelofibrosis, ovarian cancer, prostate cancer, breast cancer, chronic myeloid leukaemia, myelodysplastic syndromes, oesophageal cancer and pancreatic cancer. This article summarizes the milestones in the development of sonidegib leading to the first approvals for advanced and locally advanced BCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pramanik D. Development of hedgehog pathway inhibitors (HPI) in treatment of cancer. Curr Chem Biol. 2014;8(3):132–48.

    Article  Google Scholar 

  2. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Wang C, Wu H, Katritch V, et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature. 2013;497(7449):338–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Novartis. Odomzo® (sonidegib) capsules, for oral use: US prescribing information. 2015. http://www.accessdata.fda.gov/. Accessed 27 July 2015.

  5. Novartis. FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer [media release]. 24 July 2015. https://www.novartis.com/news/news-archive.

  6. U.S. Food and Drug Administration. FDA approves new treatment for most common form of advanced skin cancer [media release]. 24 July 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm.

  7. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28.

    Article  CAS  PubMed  Google Scholar 

  8. Novartis. Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients [media release] 20 August 2015.

  9. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735–44.

    Article  CAS  PubMed  Google Scholar 

  10. Fu J, Rodova M, Nanta R, et al. NPV-LDE-225 (erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. Neuro Oncol. 2013;15(6):691–706.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. D’Amato C, Rosa R, Marciano R, et al. Inhibition of hedgehog signalling by NVP-LDE225 (erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014;111(6):1168–79.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Nanta R, Shankar S, Srivastava RK. NPV-LDE-225 (erismodegib) inhibits human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128 [abstract no. 3193]. Cancer Res. 2013;73(8 Suppl 1). doi:10.1158/1538-7445.AM2013-3193.

  13. Yang S, Brown RD, Loh YS, et al. Blockade of the hedgehog signaling pathway by the novel agent NVP-lde225 induces differentiation, prevents de-differentiation and inhibits proliferation of multiple myeloma stem cells in vitro [abstract no. 3950]. In: 54th ASH annual meeting; 2012.

  14. Meng F, Huang K, Jiang X, et al. Hedgehog inhibitor NVP-LDE225 enhances sensitivity of chemoresistant acute myeloid leukemia cells to chemotherapeutics by down-regulating MRP1 via a mechanism involving IGF-1R/PI3K/AKT signaling. Haematologica. 2014;99(Suppl 1):551–2.

    Google Scholar 

  15. Fendrich V, Wiese D, Waldmann J, et al. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann Surg. 2011;254(5):818–23.

    Article  PubMed  Google Scholar 

  16. Jalili A, Mertz KD, Romanov J, et al. NVP-LDE225, a potent and selective Smoothened antagonist reduces melanoma growth in vitro and in vivo. PLoS One. 2013;8(7):e69064.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Steg AD, Katre AA, Bevis KS, et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther. 2012;11(7):1587–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Heller E, Hurchla MA, Xiang J, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012;72(4):897–907.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Maier T, Kulichova D, Ruzicka T, et al. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression. J Am Acad Dermatol. 2014;71(4):725–30.

    Article  CAS  PubMed  Google Scholar 

  20. Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–9.

    Article  CAS  PubMed  Google Scholar 

  21. Migden M, Lear J, Gutzmer R, et al. Inhibition of the hedgehog pathway with sonidegib (LDE225) in advanced basal cell carcinoma [abstract no. 1373]. J Am Acad Dermatol. 2015;72(Suppl 1):AB186.

  22. Zollinger M, Lozac’h F, Hurh E, et al. Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63–75.

    Article  CAS  PubMed  Google Scholar 

  23. Zhou J, Hurth E, Emotte C, et al. Evaluation of CYP3A4 endogenous biomarkers in a sonidegib drug- drug interaction study with rifampicin and ketoconazole in healthy subjects [abstract no. LBI-021]. In: American society for clinical pharmacology and therapeutics annual meeting; 2014.

  24. Kieran M, Geoerger B, Casanova M, et al. A phase 1/2 safety and preliminary efficacy study of sonidegib (LDE225), a hedgehog pathway inhibitor, in pediatric and adult patients with relapsed or refractory medulloblastoma and other solid tumors [abstract no. NO-068]. Neurooncology. 2013;15(3):iii115.

  25. Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis [abstract]. In: 56th annual meeting of the American society of hematology; 2014.

  26. Pietanza MC, Krug LM, Varghese AM, et al. Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC) [abstract no. 7602]. J Clin Oncol. 2014;32(15 Suppl 1):7602.

  27. Ottmann O, Charbonnier A, Steegmann JL, et al. Smoothened (Smo) inhibitor LDE225 combined with nilotinib in patients with chronic myeloid leukemia (CML) resistant/intolerant (R/I) to at least 1 prior tyrosine kinase inhibitor: a phase 1b study [abstract no. P231]. In: European hematology association congress; 2015.

  28. Shou Y, Robinson DM, Amakye DD, et al. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015;21(3):585–93.

    Article  CAS  PubMed  Google Scholar 

  29. Martin M, Ruiz-Borrego M, Trigo JM, et al. A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study) [abstract no. OT1-1-06]. Cancer Res. 2015;75(Suppl 9). doi:10.1158/1538-7445.SABCS14-OT1-1-06.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. C. B. Burness is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Celeste B. Burness

Authors
  1. Celeste B. Burness
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Celeste B. Burness.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burness, C.B. Sonidegib: First Global Approval. Drugs 75, 1559–1566 (2015). https://doi.org/10.1007/s40265-015-0458-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0458-y

Keywords

Search

Navigation